agilent technologies inc. - A

A

Close Chg Chg %
132.06 1.77 1.34%

Closed Market

133.83

+1.77 (1.34%)

Volume: 2.07M

Last Updated:

Nov 22, 2024, 3:59 PM EDT

Company Overview: agilent technologies inc. - A

A Key Data

Open

$131.88

Day Range

131.50 - 134.32

52 Week Range

123.48 - 155.35

Market Cap

$37.94B

Shares Outstanding

287.33M

Public Float

286.14M

Beta

1.07

Rev. Per Employee

N/A

P/E Ratio

27.37

EPS

$4.84

Yield

71.48%

Dividend

$0.25

EX-DIVIDEND DATE

Dec 31, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.95M

 

A Performance

1 Week
 
5.33%
 
1 Month
 
2.80%
 
3 Months
 
-4.99%
 
1 Year
 
5.70%
 
5 Years
 
69.16%
 

A Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About agilent technologies inc. - A

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

A At a Glance

Agilent Technologies, Inc.
5301 Stevens Creek Boulevard
Santa Clara, California 95051
Phone 1-408-553-2424 Revenue 6.83B
Industry Medical Specialties Net Income 1.24B
Sector Health Technology Employees 18,100
Fiscal Year-end 10 / 2024
View SEC Filings

A Valuation

P/E Current 27.369
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 24.675
Price to Sales Ratio 4.478
Price to Book Ratio 5.166
Price to Cash Flow Ratio 17.267
Enterprise Value to EBITDA 16.802
Enterprise Value to Sales 4.669
Total Debt to Enterprise Value 0.091

A Efficiency

Revenue/Employee 377,513.812
Income Per Employee 68,508.287
Receivables Turnover 4.912
Total Asset Turnover 0.642

A Liquidity

Current Ratio 2.611
Quick Ratio 1.968
Cash Ratio 0.992

A Profitability

Gross Margin 54.427
Operating Margin 23.826
Pretax Margin 19.596
Net Margin 18.147
Return on Assets 11.646
Return on Equity 22.242
Return on Total Capital 14.181
Return on Invested Capital 14.729

A Capital Structure

Total Debt to Total Equity 49.598
Total Debt to Total Capital 33.154
Total Debt to Total Assets 26.935
Long-Term Debt to Equity 48.811
Long-Term Debt to Total Capital 32.628
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Agilent Technologies Inc. - A

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
5.34B 6.32B 6.85B 6.83B
Sales Growth
+3.41% +18.36% +8.37% -0.22%
Cost of Goods Sold (COGS) incl D&A
2.50B 2.90B 3.16B 3.11B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
308.00M 321.00M 317.00M 271.00M
Depreciation
119.00M 122.00M 120.00M 128.00M
Amortization of Intangibles
189.00M 199.00M 197.00M 143.00M
COGS Growth
+5.66% +15.70% +9.19% -1.52%
Gross Income
2.84B 3.42B 3.69B 3.72B
Gross Income Growth
+1.50% +20.70% +7.68% +0.90%
Gross Profit Margin
+53.12% +54.17% +53.83% +54.43%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.88B 2.06B 2.10B 2.09B
Research & Development
397.00M 441.00M 467.00M 481.00M
Other SG&A
1.48B 1.61B 1.64B 1.61B
SGA Growth
+1.13% +9.30% +2.33% -0.62%
Other Operating Expense
- - - -
-
Unusual Expense
60.00M (78.00M) 66.00M 316.00M
EBIT after Unusual Expense
895.00M 1.45B 1.52B 1.31B
Non Operating Income/Expense
24.00M (5.00M) 70.00M 120.00M
Non-Operating Interest Income
8.00M 2.00M 9.00M 51.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
77.00M 80.00M 82.00M 93.00M
Interest Expense Growth
+5.48% +3.90% +2.50% +13.41%
Gross Interest Expense
77.00M 80.00M 82.00M 93.00M
Interest Capitalized
- - - -
-
Pretax Income
842.00M 1.36B 1.50B 1.34B
Pretax Income Growth
-8.38% +61.52% +10.59% -10.97%
Pretax Margin
+15.77% +21.52% +21.96% +19.60%
Income Tax
123.00M 150.00M 250.00M 99.00M
Income Tax - Current - Domestic
10.00M 139.00M 195.00M 129.00M
Income Tax - Current - Foreign
84.00M (3.00M) 47.00M 26.00M
Income Tax - Deferred - Domestic
- 5.00M (27.00M) (94.00M)
Income Tax - Deferred - Foreign
24.00M 14.00M 35.00M 38.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
719.00M 1.21B 1.25B 1.24B
Minority Interest Expense
- - - -
-
Net Income
719.00M 1.21B 1.25B 1.24B
Net Income Growth
-32.87% +68.29% +3.64% -1.12%
Net Margin Growth
+13.47% +19.15% +18.31% +18.15%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
719.00M 1.21B 1.25B 1.24B
Preferred Dividends
- - - -
-
Net Income Available to Common
719.00M 1.21B 1.25B 1.24B
EPS (Basic)
2.3269 3.9803 4.194 4.2177
EPS (Basic) Growth
-31.78% +71.06% +5.37% +0.57%
Basic Shares Outstanding
309.00M 304.00M 299.00M 294.00M
EPS (Diluted)
2.3045 3.9414 4.18 4.1892
EPS (Diluted) Growth
-31.57% +71.03% +6.05% +0.22%
Diluted Shares Outstanding
312.00M 307.00M 300.00M 296.00M
EBITDA
1.26B 1.69B 1.90B 1.90B
EBITDA Growth
- +7.76% +33.65% +12.50%
EBITDA Margin
+23.66% +26.71% +27.73% +27.79%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 150.60
Number of Ratings 21 Current Quarters Estimate 1.376
FY Report Date 01 / 2025 Current Year's Estimate 5.653
Last Quarter’s Earnings 1.41 Median PE on CY Estimate N/A
Year Ago Earnings 5.24 Next Fiscal Year Estimate 6.20
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 18 13
Mean Estimate 1.38 1.31 5.65 6.20
High Estimates 1.43 1.40 6.05 6.42
Low Estimate 1.34 1.25 5.46 5.98
Coefficient of Variance 2.12 3.28 2.15 1.65

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 2 1 1
HOLD 11 12 13
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Agilent Technologies Inc. - A

Date Name Shares Transaction Value
Aug 23, 2024 Padraig Mcdonnell President and CEO; Director 24,118 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $145 per share 3,497,110.00
Jul 23, 2024 Dominique P. Grau Senior Vice President 51,772 Bona fide gift Non-derivative transaction at $133.56 per share 6,914,668.32
Jul 4, 2024 Bret Morgan DiMarco Senior Vice President 1,618 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $125.78 per share 203,512.04
Jul 4, 2024 Bret Morgan DiMarco Senior Vice President 4,595 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 12, 2024 Dominique P. Grau Senior Vice President 49,486 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $133.28 per share 6,595,494.08
Jun 5, 2024 Padraig Mcdonnell President and CEO; Director 29,992 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $131.4 per share 3,940,948.80
May 31, 2024 George A. Scangos Director 18,578 Bona fide gift Non-derivative transaction at $145.48 per share 2,702,727.44
May 31, 2024 George A. Scangos Director 17,893 Bona fide gift Non-derivative transaction at $145.48 per share 2,603,073.64
May 21, 2024 Angelica Riemann Senior Vice President 15,255 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.23 per share 2,352,778.65
May 9, 2024 Simon May Senior Vice President 4,235 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $142.8 per share 604,758.00
May 9, 2024 Simon May Senior Vice President 11,792 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Henrik Ancher-Jensen Sr Vice President 82,560 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $139.45 per share 11,512,992.00
Mar 28, 2024 Philip Binns Senior Vice President 9,997 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $147.54 per share 1,474,957.38
Mar 20, 2024 Mikael Dolsten Director 5,711 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 842,258.28
Mar 20, 2024 Mala Anand Director 12,728 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 1,877,125.44
Mar 20, 2024 Daniel K. Podolsky Director 35,082 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 5,173,893.36
Mar 20, 2024 Otis W. Brawley Director 7,305 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 1,077,341.40
Mar 20, 2024 Sue H. Rataj Director 26,611 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 3,924,590.28
Mar 20, 2024 Dow R. Wilson Director 16,136 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.48 per share 2,379,737.28
Mar 20, 2024 Boon Hwee Koh Director 60,204 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $147.48 per share 8,878,885.92

Agilent Technologies Inc. in the News